QA: Larimar Therapeutics Inc. in us_pharma/2017

Table of Contents

See also this year's filing and all EDGAR filings for this company.

PDF Report 0001374690_2018_Larimar_Therapeutics_Inc.pdf

Logs

warning No LiabilitiesAndStockholdersEquity node found input.sec.calculation_linkbase.edgar_model_mapping {'lase_node': None, 'equity_node': None, 'partners_cap_node': None, 'nodes': "NodeView(('AssetsCurrent', 'Assets', 'PropertyPlantAndEquipmentNet', 'OtherAssetsNoncurrent', 'CashAndCashEquivalentsAtCarryingValue', 'AvailableForSaleSecuritiesDebtSecuritiesCurrent', 'TaxIncentiveReceivableCurrent', 'PrepaidExpenseAndOtherAssetsCurrent', 'LiabilitiesCurrent', 'Liabilities', 'LongTermNotesPayable', 'AccountsPayableCurrent', 'AccruedLiabilitiesCurrent', 'NotesPayableCurrent', 'PreferredStockValue', 'StockholdersEquity', 'CommonStockValue', 'AdditionalPaidInCapitalCommonStock', 'RetainedEarningsAccumulatedDeficit', 'AccumulatedOtherComprehensiveIncomeLossNetOfTax'))"}
info Failed to set obs_EconomicCapitalRatio industry.us_generic {'reason': "KeyError('0001374690')"}

Graph

Absolute values for 0001374690, Larimar Therapeutics Inc.

  xvar xval
0 AssetsCurrent 104,925,000
1 IntangibleAssetsNetIncludingGoodwill 0
2 PropertyPlantAndEquipmentNet 528,000
3 remainder_Assets 57,000
4 LiabilitiesCurrent 7,293,000
5 LiabilitiesNoncurrent 0
6 remainder_Liabilities 20,000,000
7 CostOfGoodsAndServicesSold 0
8 SellingGeneralAndAdministrativeExpense 12,160,000
9 ResearchAndDevelopmentExpense 40,839,000
10 remainder_Expenses 0
11 remainder_Revenues 0
12 remainder_NetIncome 971,000
13 remainder_ComprehensiveNetIncome 22,000
  yvar yval
0 Assets 105,510,000
1 Liabilities 27,293,000
2 Expenses 52,999,000
3 Revenues 0
4 StockholdersEquity 78,217,000
5 NetIncome -52,028,000
6 ComprehensiveNetIncome -52,017,000
7 BaseVar 93,397,500
8 EconomicCapitalRatio 1.24

Edgar->Model Mapping

Feature Distribution

Change over Time